Correction to: British Journal of Cancer (2010) 102, 232–233. doi: 10.1038/sj.bjc.6605446
Upon publication of this Letter to the Editor, it was noted that the affiliation for Dr Mark Nuijten had been presented incorrectly. The correct affiliation for Dr Nuijten is ‘Ars Accessus Medica in Amsterdam, Dorpsstraat 75 1546 LG, The Netherlands’.
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
Additional information
The online version of the original article can be found at 10.1038/sj.bjc.6605446
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Nuijten, M., Mickisch, G. Erratum: Letter to the Editor: SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival. Br J Cancer 102, 1078 (2010). https://doi.org/10.1038/sj.bjc.6605613
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6605613
